ABUS vs COF · P/E 5.4, rev $6.2M vs P/E 62, rev $53.43B
Arbutus Biopharma Corp (ABUS) versus Capital One Financial Corporation (COF) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Capital One Financial Corporation (COF) is a credit services company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported COF revenue for 2025-12-31 was $53.43B. Net income was $2.45B. Revenue was up 36.6% from 2024-12-31 to 2025-12-31. COF currently screens at market cap $125.00B and trailing P/E 61.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. COF currently screens at market cap $125.00B and trailing P/E 61.8.
Not investment advice. Open the ABUS and COF stock pages for the full models.
Not investment advice.